The discovery of the pathogenetic role of BCR-ABL and the advent of tyrosine kinase inhibitors has revolutionized the prognosis for Philadelphia-positive chronic myeloid leukemia (CML). Nevertheless, many challenges remain. In nine concise chapters, this book provides an expert overview of the state-of-the-art in addressing CML. Coverage includes diagnosis, risk classification, disease genetics, molecular monitoring, treatment options, prognostic factors and future prospects for disease management and the possibility of cure.
Advances in the treatment of chronic myeloid leukemia
Saglio G.;Fava C.
2013-01-01
Abstract
The discovery of the pathogenetic role of BCR-ABL and the advent of tyrosine kinase inhibitors has revolutionized the prognosis for Philadelphia-positive chronic myeloid leukemia (CML). Nevertheless, many challenges remain. In nine concise chapters, this book provides an expert overview of the state-of-the-art in addressing CML. Coverage includes diagnosis, risk classification, disease genetics, molecular monitoring, treatment options, prognostic factors and future prospects for disease management and the possibility of cure.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
